BNTX BioNTech SE

By Cecilia Butini

BioNTech SE on Monday posted lower revenue and profit for the fourth quarter of 2022, and said it expects a fall in revenue from its Covid-19 vaccines in the current year.

The Germany-based biotechnology company posted net profit of 2.28 billion euros ($2.45 billion) in the final quarter of the year, down from EUR5.53 billion the year prior, on revenue which slid to EUR4.28 billion from EUR3.17 billion in the same quarter of 2021. Diluted earnings per share also fell to EUR9.26 from EUR12.18 in the fourth quarter of 2021, the company said.

In 2023, BioNTech expects Covid-19 vaccine revenue to total about EUR5 billion, based on an expected transition from an advanced purchase agreement environment to commercial market ordering, the company said. For 2022, the company had guided for revenue from Covid-19 vaccines of between EUR13 billion and EUR17 billion.

"While a vaccine adaptation is expected to lead to an increased demand, fewer primary vaccinations and lowered population-wide levels of boosting are anticipated," it added.

In 2022, the company invoiced about 2 billion doses of its Covid-19 shot Comirnaty, including about 550 million of its Omicron-adapted bivalent vaccine, it said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

March 27, 2023 07:35 ET (11:35 GMT)

BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024